Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials - Krick, Stefanie; McCoy, Karen; Goss, Christopher; Weiner, Daniel; Billings, Joanne; Ren, Clement; Atkinson, Jeffrey; Linnemann, Rachel; Trimble, Aaron; Frederick, Carla; Liou, Theodore; Escobar, Hugo; et al. (The Lancet Respiratory Medicine, 2025)